As described above, increased MELK expression was already reported in a variety of solid (breast, prostate, etc.)and hematological cancers (leukemia and multiple myeloma), and has been associated with a worse clinical outcome for these patients6,14–18. This evidence concerns the gene MELK and AL amyloidosis.